Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Unsal, M. Guler, R. Ofluoglu, N. Capan (Ankara, Turkey). Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis. Eur Respir J 2011; 38: Suppl. 55, 3303

Member's Comments

No comment yet.

Related content which might interest you: Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Evaluation of the multidrug resistant TB in children with HIV infection Source: Eur Respir J 2004; 24: Suppl. 48, 439s Year: 2004 Evaluation of characteristics and treatment results of patients treated as multidrug resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Multidrug resistant tuberculosis in non HIV patients Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Factors preventing better treatment completion among MDR TB cases in a rich-resource setting Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Follow-up and treatment of patients who were diagnosed multidrug resistant tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006 Outcomes of patients with multidrug resistant tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Factors affecting outcomes of individualised treatment for drug resistant tuberculosis in an endemic region> Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Treatment outcome of multidrug resistant tuberculosis with second line drugs Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Application of therapeutic pneumoperitoneum for multi-drug resistant cavitary TB in HIV – infected patients Source: Eur Respir J 2004; 24: Suppl. 48, 650s Year: 2004 Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005